Biofrontera Inc. Announces Last Patient Enrolled In Phase 3 Clinical Study Evaluating Ameluz-PDT For The Treatment Of Basal Cell Carcinoma, Trial Results Expected In Mid-2024
Portfolio Pulse from Happy Mohamed
Biofrontera Inc. (NASDAQ:BFRI) has completed patient enrollment for its Phase 3 clinical study evaluating Ameluz-PDT in combination with the BF-RhodoLED lamp for the treatment of basal cell carcinoma (BCC). The study is a significant step in the company's strategy to expand the Ameluz label beyond actinic keratosis (AK). The results of the study are expected in mid-2024.
August 10, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biofrontera's completion of patient enrollment for its Phase 3 clinical study could potentially boost investor confidence in the company's ability to expand the Ameluz label.
The completion of patient enrollment for the Phase 3 clinical study signifies progress in Biofrontera's strategy to expand the Ameluz label. This could potentially boost investor confidence in the company's ability to deliver on its strategic objectives, thereby having a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100